NCT00316784已完成3 期
A Double-Blind, Placebo-Controlled Evaluation of Dose Related Safety and Efficacy of Epicutaneously Applied IDEA-033 for 3 Months Treatment of OA of the Knee Followed by a Double-Blind, Dose-Controlled Evaluation of Safety and Efficacy of Epicutaneously Applied IDEA-033 for 12 Weeks Treatment of OA of the Knee
IDEA AG0 个研究点目标入组 704 人开始时间: 2005年7月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 704
- 主要终点
- change from baseline at week 12 (or end of study measurements) on the Visual Analogue Scale version of the entire WOMAC Pain subscale (primary)
研究概览
简要总结
The study objective is the eluciation of the dose-response function in efficacy (and possibly safety) in order to determine an optimal dose with respect to efficacy and safety. The study is designed with three dose levels and one placebo control.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •clinical diagnosis of OA in at least one knee for a minimum of 6 months
- •aged 18-75 years old
- •eligible subjects must have used an oral or rectal NSAID on at least three days per week during the three months before screening or on at least 25 of the 30 days before screening, but be dissatisfied with the current NSAID treatment
- •at baseline visit WOMAC pain subscale at least 40 mm, and at least 15 mm greater than at the screening visit in the index knee
- •radiographic evidence consistent with OA criteria of grade 2 or 3 according to Kellgren & Lawrence in the index knee. Radiographs mus have been taken during the 6 months before baseline.
- •American College of Rheumatology (ACR) functional class I, II or III
排除标准
- •intraarticular injections or arthroscopy of the index knee within 3 months prior to screening, or planned during the study
- •history, physical examinations or radiographs suggestive of other rhematic diseases
- •known hypersensitivity or contraindication to ketoprofen; NSAID idiosyncrasy
- •history of peptic ulcers
- •severe liver or gastro-intestinal disease within the last 6 months
- •injections or change in oral treatment regimen of glucosamine, chondroitin sulfate, hyaluronic acid, shark cartilage, or vitamin E within 3 months prior to screening
- •oral or parenteral corticosteroids within 3 months prior to screening
- •analgesic therapy for chronic or recurrent pain conditions for indications other than OA
- •immunosuppressants within 3 months prior to screening
结局指标
主要结局
change from baseline at week 12 (or end of study measurements) on the Visual Analogue Scale version of the entire WOMAC Pain subscale (primary)
patient global assessment of response to therapy measured on a 5-point Likert Scale at week 12 or end of study measurements (co-primary)
change from baseline at week 12 (or end of study measurements) on the Visual Analogue Scale version of the entire WOMAC function subscale (co-primary)
次要结局
- Change from baseline at week 12 (or end of study measurements) for Physician's Global Assessment of OA and for observed function (TUG)
- Mean number of rescue medication taken per day while in the study
- Number of withdrawals and time to discontinuation of the study due to lack of efficacy
- Time to onset (in days) of pain relief and time to onset of new flares during treatment
- Change from baseline on the vitality subscale of the SF-36 health survey and the EURO QoL
研究者
相似试验
已完成
2 期
Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant EpilepsyDrug-resistant EpilepsyFocal-Onset SeizuresNCT03373383UCB Biopharma S.P.R.L.411
已完成
2 期
Comparative Trial to Investigate the Efficacy and Safety of Desmopressin for the Treatment of Nocturia in Adult WomenNocturiaNCT01684800Ferring Pharmaceuticals178
已完成
2 期
Comparative Trial to Investigate the Efficacy and Safety of Desmopressin for the Treatment of Nocturia in Adult MenNocturiaNCT01694498Ferring Pharmaceuticals183
已完成
1 期
Evaluation of the Safety and Potential Therapeutic Effects of Cordstem-ST in Patients With Cerebral InfarctionCerebral InfarctionNCT02378974CHABiotech CO., Ltd18
已完成
2 期
Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use DisorderOpioid Use DisorderNCT06384157Indivior Inc.300